Abcam, ab250368, Anti-Protective protein/Cathepsin A (PPCA) antibody [EPR10434] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Protective protein/Cathepsin A (PPCA) antibody. Carrier free. Suitable for IP, WB and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR10434,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250368 is the carrier-free version of
ab181129
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Protective protein/Cathepsin A (PPCA) also known as cathepsin A or protective proteins is an enzyme with a molecular mass of approximately 54 kDa. The enzyme is expressed widely in different tissues including liver kidney and the central nervous system. Mechanically PPCA plays a role as a carboxypeptidase with serine-type protease activity important for the stabilization and activation of lysosomal enzymes such as beta-galactosidase and neuraminidase. This stabilization is vital for proper lysosomal function and the breakdown of glycoproteins within the cell.
Biological function summary
In conjunction with these enzymes PPCA forms part of the lysosomal multienzyme complex. It regulates the degradation of sialylated glycoconjugates by ensuring the structural integrity and enzymatic activity of lysosomal enzymes. This regulation prevents the accumulation of substrate materials which can disrupt cellular homeostasis. PPCA's interaction with beta-galactosidase and neuraminidase enables the proper catabolism of glycoproteins and glycolipids which is essential for cellular functions.
Pathways
PPCA functions within the lysosomal storage and sialic acid catabolism pathways. These pathways are significant for the degradation and recycling of macromolecules in the lysosome maintaining cellular health. In the sialic acid metabolism pathway PPCA pairs with neuraminidase to break down sialylated substrates while interacting closely with beta-galactosidase in glycoprotein catabolism. These interactions highlight its role in preserving the efficiency of lysosomal degradation processes.
Mutations in the PPCA gene can lead to diseases like galactosialidosis and neuraminidase deficiency. Galactosialidosis arises from defective cathepsin A activity disrupting normal glycoprotein breakdown and resulting in storage disorders. This condition involves both beta-galactosidase and neuraminidase which accumulate as a result of PPCA dysfunction. Similarly neuraminidase deficiency exhibits symptoms due to impaired degradation of sialic acids indicating the necessity of PPCA in disease prevention.